End-of-day quote
Korea S.E.
23:00:00 20/05/2024 BST
|
5-day change
|
1st Jan Change
|
6,390
KRW
|
-0.31%
|
|
-1.99%
|
-27.22%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
645,305
|
464,141
|
915,063
|
709,999
|
269,879
|
291,422
|
Enterprise Value (EV)
1 |
621,283
|
409,640
|
859,183
|
617,120
|
193,300
|
234,641
|
P/E ratio
|
37.7
x
|
-90.9
x
|
75.6
x
|
73.1
x
|
-23,726
x
|
-30.1
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
1.14%
|
Capitalization / Revenue
|
31.3
x
|
55.6
x
|
20.1
x
|
24.2
x
|
19.3
x
|
30.4
x
|
EV / Revenue
|
30.2
x
|
49.1
x
|
18.9
x
|
21.1
x
|
13.8
x
|
24.5
x
|
EV / EBITDA
|
102
x
|
-139
x
|
49.6
x
|
53.1
x
|
2,204
x
|
-171
x
|
EV / FCF
|
163
x
|
-143
x
|
-183
x
|
18.8
x
|
-533
x
|
-27.4
x
|
FCF Yield
|
0.61%
|
-0.7%
|
-0.55%
|
5.31%
|
-0.19%
|
-3.65%
|
Price to Book
|
8.3
x
|
7.25
x
|
10.7
x
|
7.01
x
|
2.54
x
|
3.01
x
|
Nbr of stocks (in thousands)
|
29,945
|
29,945
|
32,857
|
33,729
|
33,195
|
33,192
|
Reference price
2 |
21,550
|
15,500
|
27,850
|
21,050
|
8,130
|
8,780
|
Announcement Date
|
19/03/19
|
18/03/20
|
17/03/21
|
16/03/22
|
20/03/23
|
13/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
20,584
|
8,347
|
45,433
|
29,308
|
14,007
|
9,585
|
EBITDA
1 |
6,106
|
-2,945
|
17,305
|
11,614
|
87.7
|
-1,373
|
EBIT
1 |
5,166
|
-4,368
|
15,736
|
10,077
|
-1,479
|
-3,285
|
Operating Margin
|
25.1%
|
-52.33%
|
34.64%
|
34.38%
|
-10.56%
|
-34.27%
|
Earnings before Tax (EBT)
1 |
7,312
|
-1,915
|
17,051
|
10,575
|
8,319
|
-10,837
|
Net income
1 |
8,711
|
-3,187
|
14,948
|
9,728
|
5,712
|
-9,695
|
Net margin
|
42.32%
|
-38.18%
|
32.9%
|
33.19%
|
40.78%
|
-101.15%
|
EPS
2 |
571.0
|
-170.5
|
368.2
|
288.0
|
-0.3427
|
-292.1
|
Free Cash Flow
1 |
3,810
|
-2,857
|
-4,705
|
32,785
|
-362.7
|
-8,555
|
FCF margin
|
18.51%
|
-34.23%
|
-10.36%
|
111.86%
|
-2.59%
|
-89.25%
|
FCF Conversion (EBITDA)
|
62.39%
|
-
|
-
|
282.29%
|
-
|
-
|
FCF Conversion (Net income)
|
43.73%
|
-
|
-
|
337.02%
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
100.0
|
Announcement Date
|
19/03/19
|
18/03/20
|
17/03/21
|
16/03/22
|
20/03/23
|
13/03/24
|
Fiscal Period: December |
2022 Q2
|
2022 Q3
|
2023 Q3
|
---|
Net sales
1 |
2.733
|
2.829
|
1.671
|
EBITDA
|
-
|
-
|
-
|
EBIT
|
-1.518
|
-0.4623
|
-
|
Operating Margin
|
-55.55%
|
-16.34%
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
Announcement Date
|
16/08/22
|
14/11/22
|
14/11/23
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
24,023
|
54,501
|
55,881
|
92,880
|
76,580
|
56,781
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
3,810
|
-2,857
|
-4,705
|
32,785
|
-363
|
-8,555
|
ROE (net income / shareholders' equity)
|
25.1%
|
-6.12%
|
19.9%
|
10.4%
|
5.5%
|
-9.56%
|
ROA (Net income/ Total Assets)
|
6.43%
|
-3.8%
|
10.4%
|
4.96%
|
-0.63%
|
-1.71%
|
Assets
1 |
135,475
|
83,956
|
144,059
|
196,078
|
-909,395
|
565,693
|
Book Value Per Share
2 |
2,597
|
2,137
|
2,595
|
3,005
|
3,199
|
2,914
|
Cash Flow per Share
2 |
1,411
|
1,781
|
1,824
|
2,229
|
778.0
|
1,235
|
Capex
1 |
551
|
300
|
4,852
|
3,046
|
2,229
|
7,791
|
Capex / Sales
|
2.67%
|
3.6%
|
10.68%
|
10.39%
|
15.91%
|
81.28%
|
Announcement Date
|
19/03/19
|
18/03/20
|
17/03/21
|
16/03/22
|
20/03/23
|
13/03/24
|
|
1st Jan change
|
Capi.
|
---|
| -27.22% | 156M | | +8.63% | 114B | | +13.17% | 107B | | -12.76% | 22.22B | | -2.47% | 21.28B | | -7.19% | 17.51B | | -39.93% | 17.17B | | +6.67% | 14.14B | | +33.90% | 12.2B | | -28.60% | 7.83B |
Bio Therapeutic Drugs
|